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Purpose:  Boswellia serrata, a common medicinal plant, has multiple uses in traditional medicine and, in particular, 
for the treatment of inflammatory diseases. The plant and its extracts have been evaluated for a number of activities, 
namely, anti-inflammatory, analgesic, anti-arthritic and antipyretic. In this study, the plant was subjected to 
genotoxicity studies in order to ascertain an aspect of the safety of the drug. 
Results: Dry extracts of B. serrata showed no mutagenicity up to 5 mg/plate when tested with Salmonella 
typhimurium TA97a, TA98, TA100, TA102 and TA1535 strains with or without metabolic activation. In addition, the 
extract showed significant protective effect against mutagenicity induced by mutagen in S. typhimurium TA98 and 
TA100 strains with or without metabolic activation. Similarly, in vitro chromosomal aberration assay did not reveal any 
significant alterations up to 5 mg/culture as compared to the negative control both in the presence and absence of 
metabolic activation (S9 mix).  
Conclusion: The results of these studies indicate that B. serrata is non-mutagenic in Ames test, and is protective 
against the mutagenicity induced by 4-nitroquinolene-1-oxide, sodium azide and 2-aminoflourene in TA98 and TA100 
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INTRODUCTION 
Boswellia serrata extract is used for the 
treatment of inflammatory diseases in 
Ayurvedic system of medicine. The extract is 
gummy and also used for a variety of medical 
conditions including arthritis, diarrhea, 














To the best of our knowledge, there are no 
genotoxicity data available for this plant, and, 
therefore, we have investigated the mutagenic 
activity, anti-mutagenicity and chromosomal 
aberration of the dry extract of B. serrata, a 
widely used medicinal plant in India, by Ames 
test and chromosomal aberration test based 
on Organisation for Economic Co-operation 
and Development (OECD) guidelines. 
 
MATERIALS AND METHODS 
Plant materials and chemicals 
The dry extract of B. serrata(Batch# 
NR/QCD/SPC/010) was obtained in powder 
form from Natural Remedies Pvt Ltd, 
Bangalore- 560041, India. Dimethyl sulfoxide 
(DMSO-CAS No. 67-68-5), nicotinamide 
adenine dinucleotide phosphate sodium 
(NADP-CAS No. 214-664-6), D-glucose-6-
phosphate disodium salt (CAS No. 3671-99-
6), L-histidine monohydrate (CAS No. 7048-
02-4), and D-Biotin (CAS No 58-85-5) were 
purchased from Sigma Chemical Co., while 
minimal essential medium (MEM, CAT no. 
41090-036) was procured from Gibco. S9 
microsome fraction was prepared in-house 




Standard mutagens: 2-aminofluorene (CAS 
No 613-13-8), mitomycin C (CAS No 56-07-7), 
4-nitroquinolene-1-oxide (CAS No 56-57-5), 
sodium azide (CAS No 26628-22-8), 
Benzo(α)pyrene (CAS No 200-028-5) were 
also obtained from Sigma. Oxoid nutrient 
broth No. 2 (Oxoid) and Difco bacto agar 
(Difco) were used for the preparation of 
bacterial growth media.  
Ames assay 
 S. typhimurium strains TA97a, TA98, TA100, 
TA1535 and TA102 were obtained from Bruce 
Ames Laboratory, Molecular and Cell Biology, 
University of California, and checked for their 




dependent strains of S. typhimurium TA97a, 
TA98, TA100, TA102 and TA1535 in the 
presence and absence of metabolic activation 
system (S9 liver fraction) was adopted for 
assessing the mutagenicity.  B. serrata was 
tested for its mutagenic properties at five 
different concentrations viz., 5, 2.5, 1.25, 
0.625 and 0.312 mg/plate. 100 µl of various 
concentrations of B. serrata dissolved in 
DMSO were added to 2 ml top agar mixed 
with 100µl of bacterial culture and then poured 
on to a plate containing minimal glucose agar. 
These plates were incubated at 37
0
C for 48 h 
and his+ revertant colonies were manually 
counted and the results were shown as the 
mean of the two plates with standard 
deviation. The influence of metabolic 
activation was tested by adding 500 µl of S9 
mixture. The experiments were analysed in 
triplicate and was repeated to confirm the 
result. The criteria employed to interpret the 
results of Ames test as positive were similar to 
those used in regulatory guidelines
8
. The 
number of induced mutation should be at least 
twice the activity observed in negative control 
and there must be a reproducible dose 
response curve. Concurrent positive and 
negative (DMSO) controls were used in the 
study. The standard mutagens used as 
positive controls in each experiments were 
without metabolic activation, 4-nitroquinoline-
1-oxide (5µg/plate) for strain TA97a and 
TA98, sodium azide (5µg/plate) for strain 
TA100 and TA1535, mitomycin-C 
(0.02mg/plate) for TA102. In case of positive 
controls with metabolic activation, 2-
aminoflurene (20µg/plate) for TA97a, TA98, 
TA100, TA1535 and TA102 were used. 
 
Anti-mutagenicity test 
Based on the results of mutagenicity testing, 
B. serrata was tested for its anti-mutagenic 
properties at five different concentrations viz., 
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Table 1: Mutagenic activity of dry extract of  B. serrata 
 
Revertant colonies / plate (mean 9n=3) ± S. D.) 

















184  ± 5 
187  ± 
4 
20  ± 2 20  ±3 13  ± 2 14 ± 2 181  ±  
2 




304  ± 
6 
5 
178  ± 3 
184  ± 
6 
20  ± 2 20  ± 1 12  ± 2 10  ± 1 186  ± 
4 




298  ± 
2 
2.5 
178  ±2 
187  ± 
3 
19  ± 2 20  ± 2 13  ± 3 12  ± 1 186  ± 
5 




302  ± 
3 
1.25 
178  ± 7 
188  ± 
2 
20  ± 2 21  ± 2 14  ± 2 12  ± 1 184  ± 
6 




304  ± 
5 
0.625 
179  ± 3 
188  ± 
3 
19  ± 2 21  ± 2 11  ± 1 13  ± 2 184  ± 
6 




298  ± 
2 
0.312 
178  ±5 
186  ± 
5 
20  ± 1 
20  ±  
1 
14  ± 2 12  ± 2 186  ± 
4 




302  ± 
4 




2059  ± 
15 
NA NA NA 
PC 
4NQNO 





NA NA NA NA NA NA NA 




















Key: mg = milligram, S.D. = standard deviation, NC = negative control, DMSO= dimethylSulfoxide,  
PC = positive control, 4NQNO = 4-nitroquinolene N oxide,SA = sodium azide, MMC = mitomycin C, 
 2AF = 2-aminofluorene, NA = Not Applicable, n = no. of replicates 
 
5, 2.5, 1.25, 0.625 and 0.312 mg/plate
9
. 
Dimethyl sulphoxide (DMSO) was used as 
solvent control. The S9 mix (500 µl) or 
phosphate buffer for the presence and 
absence of metabolic activation, 100 µl of the 
respective positive control (without metabolic 
activation sodium azide for TA100 and 4-
nitroquinolene-1-oxide for TA98 in case of 
with metabolic activation 2-aminofluorene for 
both the strains), 100 µl of the appropriate 
concentration of the extract, 100 µl of 
respective bacterial culture, were added to 
sterile capped tubes and incubated in an 
incubator for 30 m at 37 ± 1°C. After 
incubation, the mixture was added to sterile 
tubes containing 2 ml of top agar kept at 45 ± 
2 °C in a water bath. The tubes containing the 
mixture and top agar were gently mixed and 
then overlaid onto the surface of minimal 
glucose agar plates prepared under aseptic 
conditions contained in 100 × 10 mm plate.  
After solidification, the plates were inverted 
and incubated at 37 ± 1°C for 48–72 h.  
Plating was done in duplicates. Positive and 
negative control (DMSO) plates were also 
prepared in duplicate. The inhibition rate of 
mutagenicity (%) was calculated with respect 
to the number of revertant colonies in the 
control group treated with the corresponding 




Chromosomal aberration assay 
Chinese hamster ovary cell line obtained from 
National Centre for Cell Science, Pune was 
used for in vitro chromosomal aberration 
study. Monolayer cultures of 80% confluency 
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were cultured at a cell density of 2.3 × 10
5
 
cells per culture and after 24 h they were 
exposed to the test substance with or without 
sodium phenobarbitol-induced wister rats S9.  
As no precipitation and reduced mitotic index 
was recorded for B. serrata at 5 mg/culture, 
dose levels of 5, 2.5 and 1.25 mg/culture were 
selected and exposed to cell cultures in 
duplicate. The criteria employed to interpret 
the results of chromosomal aberration test as 
positive were similar to those used in 
regulatory guidelines
11
. Concurrent positive 
controls Mitomycin-C without S9 and 
benzo(A)pyrene with S9 and negative control 
(DMSO) were used for the study. Cell cultures 
were incubated at 37
o
C, harvested at 18h 
after exposure and stained with 5% Giemsa. A 
total of about 200 metaphases were observed 
for structural chromosome aberrations, 
including both chromosomes and chromatids 
(i.e., break, deletion, fragments and 
exchanges). Gaps were recorded but not 
included in the aberration frequency. 
RESULTS  
All the strains of S. typhimurium viz., TA97a, 
TA98, TA100, TA102 and TA1535, exposed to 
different concentrations of B. serrata, did not 
show two-fold or greater increase in the mean 
number of revertants as compared to the 
negative control group as given in Table 1. All 
strains used in the study exhibited marked 
increase (>10-fold) in the number of 
revertants when treated with positive control 
agents. The results confirmed the sensitivity of 
the tester strains to mutagens and thus the 
validity of the assay. The results indicated that 
the mean number of histidine revertants in the 
treatment groups were comparable to the 
mean number of revertants in the negative 
control group in all the five S. typhimurium 
tester strains viz., TA97a, TA98, TA100, 
TA102 and TA1535 both in the absence and 
presence of metabolic activation. Dry extract 
of B. serrata up to 5mg/plate both in the 
presence and absence of metabolic activation 
was found to be non-mutagenic to all the five 
S. typhimurium test strains.  On the other 
hand, B. serrata extract showed a significant 
dose dependent anti-mutagenic activity, in S. 
typhimurium TA98 and TA100 strain with or 
without metabolic activation (see Tables 2 and 
3). B. serrata exhibit protection against the 
mutagenicity induced by 4-nitroquinolene-1-
oxide, sodium azide and 2-aminoflourene in 
TA98 and TA100 strain 
Similarly, in vitro chromosomal aberration 
assay did not reveal any significant alterations 
up to a dose of 5mg/culture as shown in Table 
4, compared to the negative control both in 
the presence and absence of metabolic 
activation (S9 mix) but the positive controls 
induced aberration. B. serrata upto 5mg/ml 
was non-clastogenic to Chinese Hamster 
Ovary cell lines both in the presence and 
absence of metabolic activation. 
 
DISCUSSION 
Phytochemicals derived from plants or 
microbes serve as valuable sources for 
isolating and characterizing lead molecules 
with specific functions. This approach assists 
in identifying compounds that show specific 
bioactivity. B. serrata having triterpenoids
12
 as 
a main constituents is a  plant whose extract 
has been used by traditional healers in 
southern India to treat specific ailments in 
reducing pain and inflammation of joints of the 
body. It is also used for treatment of crohn 
disease  and the gum resin is used to treat 
patients with bronchial asthma 
 
and its also 
shows cytostatic and apoptosis-inducing 
activity  towards human cancer cell line in 
vitro
13
.                   
 The results obtained show that B. serrata 
extract is non-mutagenic up to dose of 
5mg/plate both in the presence and absence 
of S9 (Table 1). The absence of mutagenicity 
is not characteristic of all natural products in 
use, since other medicinal plants assayed with 
the Ames test, with or without the S9, have 
yielded positive results for mutagenicity
14
.  
The results of anti-mutagenic activities 
showed that the extract was highly effective in 
reducing the mutagenicity caused by the 
mutagen 4-nitroquinolene-1-oxide, sodium 
azide and 2-aminoflourene (Table 2 and 3). 
The mutagen 2 Aminoflurone works by 
causing framshift mutation by forming adducts 
on  the  C8  position   of   guanine  in  DNA  in  
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  Table2: Inhibition of mutagenicity by dry extract of B. serrata in S. typhimurium TA98 assay system 
 
His+ Revertant colonies / plate (mean ± S.D.) 
Dose (mg/plate) 
Presence of S9 Mix 
% inhibition of 
mutagenesis 





NC (DMSO) 21 ± 2 – 22± 2 – 
0.312 1020 ± 4 33 564 ± 4 32 
0.625 819 ± 4 46 487 ± 4 42 
1.25 665 ± 5 56 408 ± 2 52 
2.5 87 ± 3 95 61 ± 2 95 
5 21± 3 100 22 ± 4 100 
PC 1501 ± 4 – 824 ± 4 – 
Key: NC= negative control, PC= positive control 
 
 
Table3: Inhibition of mutagenicity by dry extractof B. serrata in S. typhimurium TA100 assay system 
 
His+ Revertant colonies / plate (mean ± S.D.) 
Dose (mg/plate) Presence of S9 
Mix 
% inhibition of 
mutagenesis 
Absence of S9 Mix 
% inhibition of 
mutagenesis 
NC (DMSO) 179 ± 20 – 158 ± 13 – 
0.312 635 ± 17 62.66 492  ± 41 75.12 
0.625 555 ± 30 69.21 380 ± 25 83.46 
1.25 239 ± 25 95 300 ± 31 89.42 
2.5 221± 16 96.57 250 ± 28 94.47 
5 186 ± 11 100 148 ± 25 100 
PC 1400 ± 28 – 1500 ± 69 - 
Key: NC= negative control, PC= positive control 
 













Metabolic activation –S9 +S9 
–
S9 
+S9 –S9 +S9 –S9 +S9 –S9 +S9 
No. of metaphases counted 200 200 200 200 200 200 200 200 200 200 
Ring 1 0 0 0 0 0 0 0 1 2 
Chromosomal 
Gap 
0 0 0 0 0 0 0 0 0 0 
Chromosomal 
Break 
0 0 0 0 0 1 0 0 5 4 
Chromatid Gap 0 0 0 0 0 0 0 0 0 0 
Chromatid 
break 
0 1 0 0 0 0 0 0 4 1 




Ploidy 0 0 0 0 0 0 0 0 1 4 
Total N° of Aberrations 1 1 0 0 0 1 1 0 16 14 
Total N° of Metaphases with 
Aberrations  
1 1 0 0 0 1 1 0 16 14 
Aberrations/Metaphase (Cell) 1 1 0 0 0 1 1 0 1 1 
% Metaphase with Aberrations 0.5 0.5 0 0 0 0.5 0.5 0 8 7 
  a 
Vehicle control;  
b 
dry extract of  B. serrata  (mg/ml);  
c
 positive controls; mitomycin-C (–S9) 
Benzo(α)pyrene (+S9) 
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presence of microsomal activation. In contrast 
sodium Azide requires no activation by  
hepatic microsomal enzymes to damage DNA 
and induce mutagenicity. This suggests that 
this extract may inhibit microsomal enzymes 
activation or that they may directly protect 
DNA strands from the electrophilic metabolites 
of the mutagen. Many triterpenoids have 
antioxidants depending on the redox potential, 
either accept or donate electrons, which may 
alternatively reduce them protective against 
mutagen 
15
. Our results from these 
experiments on antimutagenicity suggests that 
triterpenoids might contain antioxidants which 
protects from the mutagens. 
 In chromosomal abberation assay, no 
significant alterations were revealed up to 
5mg/culture as shown in Table 4 when 
compared to the negative control, both in the 
presence and absence of metabolic activation 
(S9 mix). Since we got no mutagneicity, 
clastogenicity and antimutagenicty we thought 
that our extract could be working with similar 
mechanisms mentioned below.  Ant 
carcinogenic/ antimutagenic activity derived 
from medicinal plants may be due to a variety 
of mechanisms such as inhibition of gentoxic 
effects, inhibition of cell proliferation, signal 
transduction modulation, antioxidant activity 
and scavenging of free radicals, induction of 
detoxication enzymes, induction of 
cytoskeletal proteins which play a key role in 
mitosis 
16
Our findings are similar to the data 
previously reported on the genotoxicity in 





The results of these studies indicate that B. 
serrata is non-mutagenic in Ames test, 
exhibits protection against the mutagenicity 
induced by 4-nitroquinolene-1-oxide, sodium 
azide and 2-aminoflourene in TA98 and 
TA100 strain, and is non-clastogenic in in vitro 
chromosomal aberration study. These 
features make the dry extract of B. serrataa a 
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